A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein

A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein

Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat advanced melanoma patients with B...

Full description

Bibliographic Details
Main Authors: Hui Li, Juan Liu, Xiaojuan Xiao, Shuming Sun, Hui Zhang, Yibin Zhang, Weihua Zhou, Bin Zhang, Mridul Roy, Hong Liu, Mao Ye, Zi Wang, Feng Liu-Smith, Jing Liu
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:Molecular Therapy: Nucleic Acids
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253119303014

Internet

http://www.sciencedirect.com/science/article/pii/S2162253119303014

Similar Items